Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in <scp>CYP2C19</scp> ‐Genotyped Patients
- DOI
- 10.1002/cpt.70506
- Published
- 2026-10-14
- Container
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1002/cpt.70506,
title = {Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in
<scp>CYP2C19</scp>
‐Genotyped Patients},
author = {Kristine Hole and Birgit M. Wollmann and Julia Carolin Stingl and Espen Molden},
year = {2026},
journal = {Clinical Pharmacology \& Therapeutics},
doi = {10.1002/cpt.70506},
url = {https://doi.org/10.1002/cpt.70506}
}RIS
TY - JOUR
TI - Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in
<scp>CYP2C19</scp>
‐Genotyped Patients
AU - Kristine Hole
AU - Birgit M. Wollmann
AU - Julia Carolin Stingl
AU - Espen Molden
PY - 2026
JO - Clinical Pharmacology & Therapeutics
DO - 10.1002/cpt.70506
UR - https://doi.org/10.1002/cpt.70506
ER - APA
Hole, K., Wollmann, B. M., Stingl, J. C., & Molden, E. (2026). Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in <scp>CYP2C19</scp> ‐Genotyped Patients. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70506
Source records
- crossref · retrieved 2026-11-11T01:13:10.135Z